Share on Google Plus Share on Twitter Share on Facebook 1 Share on LinkedIn Share on PInterest Share on Fark! Share on Reddit Share on StumbleUpon Tell A Friend 2 (3 Shares)  
Printer Friendly Page Save As Favorite View Favorites View Stats   2 comments

Exclusive to OpEdNews:
Sci Tech

Cancer Immunotherapy from Dr. Yamamoto

By (about the author)     Permalink       (Page 1 of 4 pages)
Related Topic(s): ; ; , Add Tags Add to My Group(s)

Valuable 2   Must Read 1   Well Said 1  
View Ratings | Rate It

opednews.com Headlined to H4 7/2/13

Become a Fan
  (11 fans)

Brain Metastasis From Breast Cancer (Red Arrows) by Wikimedia Commons
 



Link to original article

Left Image: CAT SCan Brain Showing enhancing metastatic lesions from breast-cancer primary. Courtesy of wikimedia commons.

This article explores the work of Dr. Yamamoto, who discovered the Macrophage-Activating Factor (GcMAF) in 1990 at the Socrates Institute in Philadelphia (4).  Since then, Dr. Yamamoto has published three human clinical trials showing remarkable results for breast (5), colo-rectal (10), and prostate cancer(11).

What is MAF -- Macrophage-Activating Factor?

MAF is a protein that activates our macrophages, the microscopic white cells that kill invading microbes and cancer cells.  MAF is made from a precursor protein called the Gc protein.

Cancer is Clever -- It Inactivates Our Immune System

In a way, cancer cells are clever little devils because they disable our immune system in order to enhance their own survival.  Dr. Yamamoto discovered that cancer cells do this by secreting an enzyme called Nagalase, which prevents the precursor protein Gc from being converted to MAF.  This Nagalase-enzyme activity can actually be measured in cancer patients, and greater tumor burden corresponds with higher Nagalase enzyme activity (as one would expect).  Elimination of the tumor results in reduction of Nagalase activity to lower, more normal values. (5)
 
Dr. Yamamoto devised a technique for restoring Gc-protein activity, which creates the most potent macrophage-activating factor ever discovered, having no adverse effects.  He called it  GcMAF.  Macrophages treated in vitro with GcMAF (100 pg/ml) are highly effective at killing breast-cancer cells.

GcMAF for Metastatic Breast Cancer -- Human Trial

Dr. Yamamoto then studied his GcMAF in human metastatic breast-cancer patients with weekly injections of 100 ng of GcMAF (5).   Dr. Yamamoto found that over time, as treatment with GcMAF  progresses, the MAF-precursor activity of patient Gc protein increased, and the serum Nagalase decreased (5).  After 5 months of weekly GcMAF injections, the cancer patients' elevated Nagalase activity had returned to normal levels, same as healthy controls.  Over the next four years, these sixteen treated metastatic breast-cancer patients remained cancer free with no recurrence (5).   In 2008, Dr. Yamamoto published his landmark study on human breast cancer.(5)


GcMAF for Metastatic Colorectal Cancer -- Human Trial

In 2008, Yamamoto published his study  on 8 patients with metastatic colorectal cancer.  They all had significant metastatic disease after primary resection (10).  Nagalase activity fell to normal levels with GcMAF injections, and remained low with no cancer recurrence over 7 years of observation.  This was supported by serial CAT scans that remained negative.

GcMAF for Metastatic Prostate Cancer -- Human Trial

Dr. Yamamoto studied GcMAF in 16 patients with metastatic prostate cancer with excellent results.  Nagalase activity declined to normal, and there was no evidence of tumor recurrence over 7 years of observation. (10)

"Sixteen nonanemic prostate-cancer patients received weekly administration of 100 ng of GcMAF. As the MAF-precursor activity increased, their serum Nagalase activity decreased. Because serum Nagalase activity is proportional to tumor burden, the entire time-course analysis for GcMAF therapy was monitored by measuring the serum Nagalase activity. After 14 to 25 weekly administrations of GcMAF (100 ng/week), all 16 patients had very low serum Nagalase levels equivalent to those of healthy control values, indicating that these patients are tumor-free. No recurrence occurred for 7 years." Quote from abstract of 2008 paper (10). 

The Saisei Mirai Clinic in Kobe, Japan

Toshio Inui, MD, of the Saisei Mirai Clinic in Kobe, Japan, has treated over 345 patients with GcMAF combined with other modalities, and reports his results in  Anticancer Research July 2013 (2,3). 

At the Saisei Mirai clinic, Dr. Inui treats cancer patients with GcMAF immunotherapy in combination with other related therapies, such as intravenous vitamin C, alpha-lipoic acid, hyperthermia, and LDN (low-dose naltrexone). Dr Inui says his results are mixed, and describes his treatment as "hopeful."  He presents three cases in which treatment was remarkably effective:

Quoted from Anticancer Research (3).

Patient 1. A 71-year-old man was diagnosed with thymic carcinoma with lung metastasis. The patient received 24 weeks of the integrative immunotherapy. No progression of the cancer was found 12 months after completion of the therapy.

Patient 2. A 74-year-old man was diagnosed with prostate cancer with multiple bone metastases. He received 12 weeks of the integrative immunotherapy combined with hyperthermia therapy. Bone scintigram results nine months after initiation of the therapy were normal and metastatic tumors had disappeared.

Patient 3. A 72-year-old woman was diagnosed with metastatic liver cancer after sigmoidectomy and bilateral oophorectomy. She received 24 weeks of the integrative immunotherapy combined with 55 Gy of radiation. There was no evidence of local recurrence or metastatic disease on Positron-Emission Tomography (PET) and Computed Tomography (CT) scans 12 months after initiation of the therapy.

Next Page  1  |  2  |  3  |  4

 

http://jeffreydachmd.com

Jeffrey Dach MD is a physician and author of two books, Natural Medicine 101, and Bioidentical Hormones 101, both available on Amazon, or as a free e-book on his web sites. Dr. Dach is founder and chief medical officer of TrueMedMD, a clinic in (more...)
 

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon

Go To Commenting
The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Follow Me on Twitter

Contact Author Contact Editor View Authors' Articles
Related Topic(s): ; ; , Add Tags

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Failed Hatchet Job on Larry King, Suzanne Somers, Knockout

Bioidentical Hormones on Oprah, Are They Safe?

Why Natural Thyroid is Better than Synthetic

Wheatgrass, Natural Medicine in the Kitchen

Fish Oil Increases Risk for Prostate Cancer, New Study?

Spontaneous Remission Cancer Breakthrough

Comments

The time limit for entering new comments on this article has expired.

This limit can be removed. Our paid membership program is designed to give you many benefits, such as removing this time limit. To learn more, please click here.

Comments: Expand   Shrink   Hide  
2 people are discussing this page, with 2 comments
To view all comments:
Expand Comments
(Or you can set your preferences to show all comments, always)

And be sure you follow the money.There's much more... by Gary Glaxon on Wednesday, Jul 3, 2013 at 2:09:41 PM
Thank you for this article!In the 1970s my dad, su... by Marta Steele on Thursday, Jul 4, 2013 at 9:43:58 AM